1. |
Aly RH, Amr NH, Saad WE, et al. Insulin resistance inpatients on valproic acid: relation to adiponectin. Acta Neurol Scand, 2015, 131(3): 169-175.
|
2. |
丁美萍, 包颖颖, 陈忠. 丙戊酸钠治疗与胰岛素抵抗. 浙江大学学报医学版, 2004, 33(3): 216-218.
|
3. |
Najafi MR, Bazooyar B, Zare M, et al. The investigation of insulin resistance in two groups of epileptic patients treated with sodium valproate and carbamazepine. Adv Biomed Res, 2017, 6: 25.
|
4. |
Rakitin A, Eglit T, Koks S, et al. Comparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia. PLoS One, 2014, 9(7): e103856.
|
5. |
Rakitin A. Doesvalproic acid have potential in the treatment of diabetes mellitus? Front Endocrinol (Lausanne), 2017, 8: 147.
|
6. |
Martin CK, Han H, Anton SD, et al. Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. J Psychopharmacol, 2009, 23(7): 814-825.
|
7. |
Ye J. Improving insulin sensitivity with HDAC inhibitor. Diabetes, 2013, 62(3): 685-687.
|